From the Guidelines
The maximum dose of Trulicity (dulaglutide) is 1.5 mg injected subcutaneously once weekly, as recommended for cardiovascular benefit and glycemic control in adults with type 2 diabetes. According to the 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes, published in the Journal of the American College of Cardiology 1, the recommended dose for Trulicity is initiated at 0.75 mg SC per week and titrated as tolerated to 1.5 mg or maximally tolerated dose based on prescribing information.
Key points to consider when prescribing Trulicity include:
- Initiating the dose at 0.75 mg SC per week to minimize gastrointestinal side effects
- Titration to 1.5 mg SC per week based on patient tolerance and glycemic response
- Contraindications such as history of serious hypersensitivity reaction to the drug, pregnancy or breastfeeding, and severe renal impairment or end-stage renal failure
- Cautions including increased risk of hypoglycemia with insulin, sulfonylureas, or glinides, and potential delay in gastric emptying
- Monitoring for adverse effects like nausea, vomiting, diarrhea, headache, weakness, or dizziness, as well as hypoglycemia and injection site reactions.
It is essential to follow the recommended dosing and titration schedule to ensure the safe and effective use of Trulicity in managing type 2 diabetes and reducing cardiovascular risk, as supported by the evidence from the Journal of the American College of Cardiology 1.
From the FDA Drug Label
The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly. The maximum dose of Trulicity is 4.5 mg injected subcutaneously once weekly 2.
- This dose is applicable for adults.
- For pediatric patients, the maximum recommended dosage is 1.5 mg once weekly 2.
From the Research
Maximum Dose of Trulicity
The maximum dose of Trulicity (dulaglutide) is not explicitly stated in the provided studies. However, the following information is available:
- The studies mention that dulaglutide is administered subcutaneously at a dose of 0.75 mg or 1.5 mg once weekly 3, 4, 5, 6.
- The efficacy and safety of dulaglutide at these doses have been demonstrated in clinical trials 3, 4, 5, 6.
- There is no mention of a higher dose being used or recommended in the provided studies.
Key Points
- Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes 3, 4, 5, 6.
- The recommended dose of dulaglutide is 0.75 mg or 1.5 mg once weekly 3, 4, 5, 6.
- Dulaglutide has been shown to be effective and generally well-tolerated in clinical trials 3, 4, 5, 6.